Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Western University Of Health Sciences focuses its patent prosecution within the Biotechnology & Pharmaceuticals technology area. The university currently has 2 pending office actions that require attention. These actions are distributed across 2 distinct examiners, which means the prosecution workload is shared between different individuals. Additionally, the portfolio is active within 2 distinct art units, indicating that the technical subject matter spans multiple specialized groups at the patent office.
The busiest examiner for this portfolio is SCHMITT, MICHAEL J, who is currently handling 1 busiest examiner pending office action. Since there are 2 pending office actions in total, this examiner is responsible for 1 of the active matters. Practitioners should be aware that with 2 distinct examiners and 2 distinct art units, the university must manage different examination styles and technical standards. The presence of 2 pending office actions across 2 distinct examiners suggests a need for a coordinated approach to ensure consistency in the university's intellectual property strategy within the Biotechnology & Pharmaceuticals sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (50%) |
| No statute on record | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHMITT, MICHAEL J | 1 | 57.0% | +20.4% |
| DAHLIN, HEATHER RAQUEL | 1 | 42.2% | +47.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18377503 | PROTEIN ARGININE METHYLTRANSFERASE 9 INHIBITORS AND METHODS OF USE | SCHMITT, MICHAEL J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17267802 | CALPAIN-2 SELECTIVE INHIBITOR COMPOUNDS FOR TREATMENT OF GLAUCOMA | DAHLIN, HEATHER RAQUEL | 34d |
| 18377503 | PROTEIN ARGININE METHYLTRANSFERASE 9 INHIBITORS AND METHODS OF USE | SCHMITT, MICHAEL J | — |
| Art Unit | Apps |
|---|---|
| 1635 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18377503 | PROTEIN ARGININE METHYLTRANSFERASE 9 INHIBITORS AND METHODS OF USE | SCHMITT, MICHAEL J | 1635 | §102§112 | Non-Final OA | — | Pending | Oct 06, 2023 |
| 17267802 | CALPAIN-2 SELECTIVE INHIBITOR COMPOUNDS FOR TREATMENT OF GLAUCOMA | DAHLIN, HEATHER RAQUEL | 1629 | Other | Final Rejection | 34d | Pending | Feb 10, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWestern University Of Health Sciences has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Michael J Schmitt has the most, with 1 of Western University Of Health Sciences's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
